Gilead Sciences is a global biopharma company with diverse portfolio and is known for its infectious disease drug portfolio.
- In Feb 2021, Gilead Sciences increases its holdings in Arcus Biosciences Inc. to 19.5% from 13% earlier through the purchase of $220.35 Mn worth of new equity issue by Arcus Biosciences.
- In Sep 2020, Gilead Sciences acquire and merge Immunomedics, Inc. (Nasdaq: IMMU) for approx $21 billion. Immunomedics was developing mAb-based products to target cancer.
- In June 2020, Gilead Sciences acquired a 49.9% equity interest in Pionyr Immunotherapeutics in $275 Mn USD, with an exclusive option to purchase the remainder of Pionyr. Under the agreement, Pionyr’s shareholders may receive up to an additional $1.47 billion in option exercise fees and future milestone payments.
- In Mar 2020, Gilead Sciences, acquired Forty Seven, Inc. at approx. $4.9 billion. Forty Seven focus on targeting the CD47 pathway as a way to engage macrophages in fighting tumors.
In Aug 2017, Gilead Sciences acquired Kite Pharma for $11.9 Billion developing CAR-T therapies against cancer. Kite pharma now operates as wholly owned subsidiary of Gilead Sciences. - In May 2015, Gilead acquired EpiTherapeutics ApS, a privately-held Danish company, for $65 Mn. EpiTherapeutics has generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead pre-clinical compounds are being studied for the treatment of certain cancers.
- In Feb 2013, Gilead acquired YM Biosciences in approximately $490.0 Mn USD and added CYT387 to its pipeline.
- In Nov 2011, Gilead acquired Arresto Biosciences (fibrotic diseases and cancer) for $225 Mn USD.
- In Feb 2011, Gilead acquired Calistoga Pharmaceuticals (cancer and inflammation) for $375 Mn USD.
Page 1 of 3
